Canakinumab

Names

[ Name ]:
Canakinumab

Biological Activity

[Description]:

Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin[1][2].

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[Target]

IC50: 43.6 pM (human IL-1β), 40.8 pM (marmoset IL-1β)[2]

[In Vitro]

Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC50s of 43.6 and 40.8 pM for human and marmoset IL-1β[2].Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b[2].

[References]

[1]. Dhimolea E. Canakinumab. MAbs. Epub 2010 Jan 15.

[2]. Rondeau JM, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015;7(6):1151-60.

Chemical & Physical Properties

No Any Chemical & Physical Properties